Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jan;37(1):160-165.
doi: 10.1111/jdv.18573. Epub 2022 Sep 23.

Comparison of topical benzyl benzoate vs. oral ivermectin in treating scabies: A randomized study

Affiliations
Randomized Controlled Trial

Comparison of topical benzyl benzoate vs. oral ivermectin in treating scabies: A randomized study

Damian Meyersburg et al. J Eur Acad Dermatol Venereol. 2023 Jan.

Abstract

Background: Scabies is an itchy, parasitic infection of the skin. Recent reports indicate there is a decreasing efficacy of the standard treatment of choice, topical 5% permethrin cream.

Objective: To evaluate the comparative efficacy, safety and tolerability of topical benzyl benzoate (BB) with oral ivermectin in the treatment of scabies.

Methods: Patients with dermoscopy-verified scabies visiting the dermatologic outpatient clinic were assessed for enrolment in the study. In total, 224 patients were enrolled and sequentially randomized into two equally sized groups. Group A received topical 25% or 10% BB for the daily use over a period of three consecutive days, group B received oral ivermectin (200 μg/kg body weight) twice, 1 week apart. Treatment outcome was evaluated by dermoscopy at a 3-week follow-up visit.

Results: Treatment resulted in a cure rate of 87% in group A and 86% in group B. After initial therapy failure in group A, six out of eight patients showed treatment response upon repeated application of BB, five of five when retreated with ivermectin and two of two with BB plus ivermectin, respectively. In group B, successful retreatment was observed in three out of three patients with ivermectin, two of two patients with BB and 11 of 11 patients with the combination of BB plus ivermectin, respectively. Tolerability and safety profile of oral ivermectin was excellent, while BB produced short burning sensations in 14%.

Conclusion: Topical BB and oral ivermectin have shown comparable good therapeutic efficacy. Therefore, both agents constitute an adequate first-line therapy in the treatment of scabies. A combination of both agents may be considered in recalcitrant and extensively infested cases, additionally to crusted scabies.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

FIGURE 1
FIGURE 1
Treatment algorithm used at the Department of Dermatology and Allergology in Salzburg, Austria (adopted from 2). Instruction for outpatient self‐treatment (or treatment conducted by parents or life‐partner), behavioural and implemented household measures should be conducted both orally and by using a standardized printed handout.

References

    1. Marks M, Engelman D, Romani L, Mason D, Sokana O, Kama M, et al. Exploration of a simplified clinical examination for scabies to support public health decision‐making. PLoS Negl Trop Dis. 2018;12:e0006996. - PMC - PubMed
    1. Salavastru CM, Chosidow O, Boffa MJ, Janier M, Tiplica GS. European guideline for the management of scabies. J Eur Acad Dermatol Venereol. 2017;31:1248–53. - PubMed
    1. Sunderkötter C, Feldmeier H, Fölster‐Holst R, Geisel B, Klinke‐Rehbein S, Nast A, et al. S1 guidelines on the diagnosis and treatment of scabies – short version. J Dtsch Dermatol Ges. 2016;14:1155–67. Extended version at: www.awmf.org - PubMed
    1. Österreichische Gesellschaft für Sexually Transmitted Diseases und dermatologische Mikrobiologie: Skabies Therapiemanagement für Allgemeinmediziner und Fachärzte. Addendum zur Version 11/2019. Available from: http://www.oegstd.at/
    1. Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1–137. - PMC - PubMed

Publication types